Table 3.
Logistic regression analysis of the factors associated with rapid virological response
| Variable | RR (95% CI) | P value |
|---|---|---|
| Univariate analysis | ||
| Pretreatment variables | ||
| Gender (male vs. female) | 1.438 (0.589–3.513) | 0.425 |
| Age (<55 vs. ≥55 years) | 1.536 (0.583–4.049) | 0.512 |
| Weight (≥60 vs. <60 kg) | 2.511 (0.938–6.723) | 0.067 |
| Treatment (naive vs. re-treatment) | 1.400 (0.354–5.530) | 0.631 |
| Genotype (1 vs. 2) | 1.773 (0.377–8.333 | 0.468 |
| Fibrosis staging (F2-4 vs. F0-1)† | 1.104 (0.356–3.425) | 0.865 |
| Grading (A2-3 vs. A0-1)† | 1.167 (0.384–3.546) | 0.786 |
| HCV RNA (kIU/mL) | ||
| <100 | 1 | |
| 100–1000 | 0.562 (0.140–2.251) | 0.415 |
| ≥1000 | 0.159 (0.048–0.526) | 0.003 |
| ALT (≥60 vs. <60 IU/l) | 1.437 (0.579–3.571) | 0.435 |
| γ-GTP (IU/l) (≥41 vs. <41 IU/l) | 3.946 (1.504–10.352) | 0.005 |
| Neutrophil count (≥2500 vs. <2500/μL) | 1.135 (0.465–2.771) | 0.782 |
| Hemoglobin (<14 vs. ≥14 g/dl) | 1.427 (0.582–3.497) | 0.437 |
| Platelet count (≥191 vs. <191 × 103/μL) | 6.567 (1.466–29.424) | 0.014 |
| Treatment-associated variables | ||
| Adherence during 4 weeks of treatment (≥80% vs. <80%) | 1.714 (0.419–7.011) | 0.453 |
| Stepwise multivariate analysis | ||
| HCV RNA (kIU/ml) | ||
| <100 | 1 | |
| 100–1000 | 0.399 (0.091–1.759) | 0.225 |
| ≥1000 | 0.126 (0.034–0.464) | 0.002 |
| Platelet count (≥191 vs. <191 × 103/μl) | 10.230 (2.056–50.902) | 0.005 |
| γ-GTP (IU/l) (≥41 vs. <41 IU/l) | 3.989 (1.355–11.744) | 0.012 |
ALT alanine aminotransferase, γ-GTP gamma glutamyl transpeptidase
†A biopsy was not available from 40 patients